

# Cristiana Bergamini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1252592/publications.pdf>

Version: 2024-02-01

39  
papers

1,914  
citations

411340

20  
h-index

388640

36  
g-index

39  
all docs

39  
docs citations

39  
times ranked

2916  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy followed by cetuximab in locally advanced/metastatic (LA/M) cutaneous squamous cell carcinomas (cSCC): The I-TACKLE trial.. Journal of Clinical Oncology, 2022, 40, 9520-9520.	0.8	5
2	Local therapies for liver metastases of rare head and neck cancers: A monoinstitutional case series. Tumori, 2021, 107, 030089162095284.	0.6	4
3	Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. Tumori, 2021, , 030089162110079.	0.6	0
4	Bleeding complications in patients with squamous cell carcinoma of the head and neck. Head and Neck, 2021, 43, 2844-2858.	0.9	12
5	A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of Aqualief™ Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. Cancers, 2021, 13, 3456.	1.7	3
6	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. Journal of Clinical Oncology, 2021, 39, 4061-4068.	0.8	24
7	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. Exploration of Targeted Anti-tumor Therapy, 2021, 2, .	0.5	3
8	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2479-2487.	1.2	12
9	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer, 2020, 126, 1888-1894.	2.0	54
10	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head and Neck, 2019, 41, 3670-3676.	0.9	29
11	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. Expert Opinion on Investigational Drugs, 2019, 28, 435-443.	1.9	8
12	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. Oral Oncology, 2018, 86, 266-272.	0.8	26
13	Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. Oral Oncology, 2017, 66, 58-63.	0.8	90
14	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncology, 2017, 69, 33-37.	0.8	16
15	Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. Supportive Care in Cancer, 2017, 25, 1787-1795.	1.0	12
16	Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?. Disease Markers, 2017, 2017, 1-9.	0.6	4
17	Safety of Combination Treatment with Imatinib Mesylate, Carboplatin, and Cetuximab in a Patient with Multiple Cancers: A Case Report. Tumori, 2016, 102, S1-S2.	0.6	1
18	Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. Head and Neck, 2016, 38, E1521-7.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016, 38, E1009-13.	0.9	6
20	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 959-966.	0.4	48
21	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	1.3	66
22	Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. <i>Clinical Cancer Research</i> , 2016, 22, 3961-3970.	3.2	65
23	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016, 38, 724-731.	0.9	104
24	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 57-75.	1.5	46
25	Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?. <i>Oral Oncology</i> , 2016, 54, 54-57.	0.8	46
26	Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. <i>Future Oncology</i> , 2014, 10, 2111-2120.	1.1	3
27	Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 884-887.	0.8	20
28	Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>Future Oncology</i> , 2013, 9, 103-114.	1.1	28
29	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	0.6	97
30	Targeted therapy in head and neck cancer. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2011, 19, 132-137.	0.8	12
31	Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. <i>Annals of Oncology</i> , 2011, 22, 2495-2500.	0.6	31
32	Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis" by Rades et coll.. <i>Oral Oncology</i> , 2010, 46, 888.	0.8	0
33	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009, 45, 574-578.	0.8	184
34	Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). <i>Oral Oncology</i> , 2009, 45, 986-990.	0.8	144
35	Effects of Treatment Intensification on Acute Local Toxicity During Radiotherapy for Head and Neck Cancer: Prospective Observational Study Validating CTCAE, Version 3.0, Scoring System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 330-337.	0.4	48
36	Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. <i>Annals of Oncology</i> , 2007, 18, 601-602.	0.6	26

#	ARTICLE	IF	CITATIONS
37	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5630-5636.	0.8	605
38	Is Restoring Platinum Sensitivity the Best Goal for Cetuximab in Recurrent/Metastatic Nasopharyngeal Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7757-7758.	0.8	7
39	Is PSA useful in the diagnosis and monitoring of parotid adenocarcinomas?. <i>Oral Oncology</i> , 2005, 41, 219-221.	0.7	0